NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lynch Regenerative Medicine

Lynch Regenerative Medicine

Private
Franklin, TennesseeHealthcare & Life Scienceshttps://lynchregen.com/

Last Round

Early Stage

VC

Jul 15, 2026

Total Funding Raised

$7.45M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Lynch Regenerative Medicine is a biotherapeutics company that develops and commercializes advanced skin rejuvenation and regeneration solutions using patented platelet-derived growth factor (PDGF) technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicinebiologicsrhPDGF-BBwound healingtissue repairbiotechgrowth factor therapyrecombinant proteinclinical stage biotechorthopedicsperiodontal regenerationdrug developmentregenerative aestheticsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lynch Regenerative Medicine Comparables

Compare Lynch Regenerative Medicine with similar companies based on industry and business-model similarity.

Lynch Regenerative Medicine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PolarityBio, Inc.
81%
Merakris Therapeutics
77%
Theradaptive
76%

Lynch Regenerative Medicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCJul 15, 2026
Series AJul 16, 2024
SeedFeb 1, 2024
AcceleratorSep 1, 2023

Key People

Founding team and executive leadership

Ginger Smith

Chief Financial Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 15, 2026

    $15M raised in early stage VC funding.

  • Jun 11, 2026

    Grew 19% QoQ, from 27 to 32 employees.

Lynch Regenerative Medicine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lynch Regenerative Medicine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Lynch Regenerative Medicine's valuation, stock price, and market status.

Firmographic Details

HeadquartersFranklin, Tennessee
Employee Range32
Year Founded2023
Last FundingJul 15, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.